End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Transplantation

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0000000000002006PMID 29189632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

  2017cited by this paper
• Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma

  2017cited by this paper
• Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children

  2016cited by this paper
• Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.

  2016cited by this paper
• International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial

  2015cited by this paper
• How I treat posttransplant lymphoproliferative disorders.

  2015cited by this paper
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

  2014cited by this paper
• F-fl uorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder

  2014cited by this paper
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

  2014influential reference
• The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder

  2013cited by this paper
• EBV and posttransplantation lymphoproliferative disease: what to do?

  2013cited by this paper
• Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

  2012cited by this paper
• Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

  2012cited by this paper
• 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

  2011cited by this paper
• PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation.

  2009influential reference
• Report on the First International Workshop on interim-PET scan in lymphoma

  2009cited by this paper
• FDG-PET/CT and SPECT/CT in Oncology

  2008cited by this paper
• Clinical Usefulness of FDG-PET/CT Scan Imaging in the Management of Posttransplant Lymphoproliferative Disease

  2008cited by this paper
• FDG-PET/CT in oncology

  2007cited by this paper
• Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

  2007cited by this paper
• How Useful is PET/CT Imaging in the Management of Post‐Transplant Lymphoproliferative Disease After Liver Transplantation?

  2006influential reference
• Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

  2006cited by this paper
• Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)

  2005cited by this paper
• Salvage chemotherapy for refractory or relapsed post‐transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide

  2003cited by this paper
• Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

  2001cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• [For children...].

  1971cited by this paper

• The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents

  2024cites this paper
• Outcomes of children treated for multiple Epstein–Barr virus‐associated post‐transplant tumors

  2023cites this paper
• Longitudinal Optical Coherence Tomography Measurement of Retinal Ganglion Cell and Nerve Fiber Layer to Assess Benign Course in Multiple Sclerosis

  2023cites this paper
• Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study

  2023cites this paper
• Solitary Central Nervous System Relapse of Posttransplant Lymphoproliferative Disorder on 18F-FDG PET/CT.

  2022cites this paper
• Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial

  2022cites this paper
• Management of PTLD after SOT

  2021cites this paper
• Clinical Features and Diagnostic Considerations

  2021cites this paper
• 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD).

  2021cites this paper
• PET-CT in Infection and Inflammation

  2021cites this paper
• Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance

  2021cites this paper
• Prognostic superiority of International Prognostic Index over [18F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder

  2021cites this paper
• Haematological disorders following kidney transplantation.

  2020cites this paper
• Real‐world outcomes of post‐transplant lymphoproliferative disorder treated with risk‐stratified sequential therapy

  2020cites this paper
• Diagnostic Performance of 18F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis

  2020cites this paper
• Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma‐type post‐transplant lymphoproliferative disorder

  2020cites this paper
• Publikationsliste Prof. Trappe 2020

  2020cites this paper
• Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant

  2020cites this paper
• Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation

  2020cites this paper
• Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed Tomography Scans in the Management of Post-Transplant Lymphoproliferative Disease in Pediatric Patient.

  2020cites this paper
• PET-CT in the Organ Transplantation

  2020cites this paper
• 18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

  2019cites this paper
• Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

  2019cites this paper
• Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cites this paper
• Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder

  2019influential citation
• Management of post‐transplant lymphoproliferative disorders

  2018cites this paper
• Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

  2018cites this paper